Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain, which is by far the most prevalent form of dementia in adults over 65 years old. Amyloid β peptide (Aβ)-containing senile plaques are one of the neuropathological hallmarks of AD. The gradual accumulation of aggregated Aβ peptide initiates a complex multistep cascade, which include gliosis, inflammatory changes, oxidative stress, tangle formation (microtubule changes), neuritic/synaptic changes, and transmitter loss that finally lead to dementia. One of the strategies used to increase the clearance of Aβ peptide from the brain involves immunization with Aβ peptide 1–42 (Aβ1–42). However, clinical trials of active immunization were halted when patients in the study developed meningocephalitis. We have recently reported that semi-allogeneic somatic cell hybrids generated by the fusion of EL-4 T lymphoma cells (H-2b) and BALB/c-derived renal adenocarcinoma RAG cells (H-2d) can protect C57BL/6 mice (H-2b) challenged with a tumorigenic dose of EL-4 cells. The results of our studies are entirely consistent with the concept that the semi-allogeneic vaccine (made of RAG X EL-4 cell hybrids) induce a potent T cell-mediated (Th-1) response, that instructs T lymphocytes to kill autologous (EL-4) tumor cells. We have subsequently modified RAG X EL-4 cell hybrids to specifically target Aβ1–42. Ten-week-old female C57BL/6 APP transgenic mice (APPswe, PSEN1dE9) were treated with a single dose of modified RAG X EL-4 somatic cell hybrids, injected intraperitoneally (i.p.). At six months of age, all mice were sacrificed and their brains were fixed and sectioned to count the amyloid plaques. We observed that the brains of APP mice, treated with a single dose of the semi-allogeneic cell hybrids formulated with Aβ1–42, showed less numerous and smaller plaques compared to the brains of APP mice treated with Aβ1–42 in PBS or with unmodified RAG X EL-4 cell hybrids in PBS. The results of these preliminary animal studies led us to hypothesize that a T cell-mediated (Th-1) immune response targeting the Aβ1–42 will help clear this peptide from the brain, resulting in enhanced cognition, without the risk of adverse events such as meningocephalitis.

Pulmonary B Lymphocytes Ameliorate Alzheimer's Disease-Like Neuropathology

Pulmonary B cells ameliorate Alzheimer’s disease-like neuropathology

B lymphocytes ameliorate Alzheimer's disease-like neuropathology via interleukin-35

B Lymphocytes Ameliorate Alzheimer’s Disease-Like Neuropathology Via Interleukin-35

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

The Combined Treatment of Amyloid-Β1-42-stimulated Bone Marrow–derived Dendritic Cells Plus Splenocytes from Young Mice Prevents the Development of Alzheimer's Disease in APPswe/PSENldE9 Mice

Rejuvenation of peripheral immune cells attenuates Alzheimer's disease-like pathologies and behavioral deficits in a mouse model

CD8 + T cells exacerbate AD-like symptoms in mouse model of amyloidosis

Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimer's Disease

Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer’s Disease Mouse Models: A Potential Role for Aβ

Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer's disease via impacting on peripheral innate immune cells

Peripheral Immune Cells and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Intact Older Adults: the CABLE Study

Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer's disease

T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function

β2-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice

Single-cell transcriptomics reveals colonic immune perturbations during amyloid-β driven Alzheimer's disease in mice

Cognitive decline, Aβ pathology, and blood–brain barrier function in aged 5xFAD mice

Treatment with Bifidobacteria can suppress Aβ accumulation and neuroinflammation in APP/PS1 mice

FAM19A5 Deficiency Mitigates the Aβ Plaque Burden and Improves Cognition in Mouse Models of Alzheimer's Disease